Breaking News

Fujifilm to Invest $40M in New Facility

State-of-the-art viral vector and advanced therapy process development and manufacturing facility will be located in Boston area.

By: Contract Pharma

Contract Pharma Staff

Fujifilm Corporation has announced an investment of approximately $40 million in Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area. This will be the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies.   The new facility is schedul...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters